Citadel Advisors
CAMP icon

Citadel Advisors’s CAMP4 Therapeutics CAMP Stock Holding History

Citadel Advisors’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-200,000
Closed -$1.04M – 14547
2024
Q4 		$1.04M Buy
+200,000
New +$1.64M ﹤0.01% 6915

Other funds holding CAMP

ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's CAMP Position: Q1 2025 in Review

Citadel Advisors sold out of CAMP4 Therapeutics (CAMP) in Q1 2025, closing a stake of 200,000 shares — an estimated $1.04M sold.

Citadel Advisors first reported a position in CAMP in Q4 2024 and held it in 1 quarter. The position peaked at $1.04M in Q4 2024. 39 funds tracked by Wall St. Rank hold CAMP as of Q1 2025.

  • Citadel Advisors reported no remaining CAMP4 Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Citadel Advisors sold 200,000 CAMP4 Therapeutics shares in Q1 2025, an estimated $1.04M.
  • Citadel Advisors first reported a position in CAMP4 Therapeutics in Q4 2024 and held it in 1 quarter.
  • Citadel Advisors's CAMP4 Therapeutics position peaked at $1.04M in Q4 2024.
  • 39 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.